BCM
ARRY

BlueCrest Capital Management’s Array Biopharma Inc ARRY Stock Holding History

BlueCrest Capital Management’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-10,498
Closed -$160K – 1673
2018
Q3 		$160K Buy
+10,498
New +$161K ﹤0.01% 1327
2018
Q2 		– Sell
-11,072
Closed -$181K – 2030
2018
Q1 		$181K Buy
+11,072
New +$177K 0.01% 1295

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlueCrest Capital Management's ARRY Position: Q4 2018 in Review

BlueCrest Capital Management sold out of Array Biopharma Inc (ARRY) in Q4 2018, closing a stake of 10,498 shares — an estimated $160K sold.

BlueCrest Capital Management first reported a position in ARRY in Q1 2018 and held it in 2 quarters. The position peaked at $181K in Q1 2018. 236 funds tracked by Wall St. Rank hold ARRY as of Q4 2018.

  • BlueCrest Capital Management reported no remaining Array Biopharma Inc position as of Q4 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 10,498 Array Biopharma Inc shares in Q4 2018, an estimated $160K.
  • BlueCrest Capital Management first reported a position in Array Biopharma Inc in Q1 2018 and held it in 2 quarters.
  • BlueCrest Capital Management's Array Biopharma Inc position peaked at $181K in Q1 2018.
  • 236 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q4 2018.

Based on BlueCrest Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.